Transdermal systems containing multilayer adhesive matrices to modify drug delivery
View Patent ↗A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.
1. A method for making a transdermal drug-containing dosage unit which comprises a laminate comprising:
contacting a backing layer substantially impervious to a drug to be delivered transdermally; with
a first polymeric adhesive matrix, having dispersed therein
a drug and having a first initial rate of delivery of the drug; contacting the first polymeric adhesive matrix with a second polymeric adhesive matrix, having dispersed therein the drug and having a second initial rate of delivery of the drug, wherein said second initial rate of delivery is different from said first initial rate of delivery; and
contacting the second polymeric adhesive matrix with a release liner.
2. The method of claim 1 , wherein said first polymeric adhesive matrix delivers said drug more slowly than said second polymeric adhesive matrix.
3. The method claim 1 , wherein said second polymeric adhesive matrix delivers said drug more slowly than said first polymeric adhesive matrix.
4. The method of claim 1 , wherein one of said first and second adhesive matrices has an initial delivery rate of a given amount of said drug that is at least about 10% faster than that of the other of said adhesive matrices.
5. The method of claim 1 , wherein either said first or said second polymeric adhesive matrix comprises an acrylic adhesive.
6. The method of claim 1 , wherein said first adhesive matrix comprises an acrylic adhesive and said second adhesive matrix comprises a silicone adhesive.
7. The method of claim 1 , wherein said first adhesive matrix comprises an acrylic adhesive and said second adhesive matrix comprises a polyisobutylene adhesive.
8. The method of claim 6 , wherein said silicone adhesive comprises a standard silicone adhesive or an amine compatible silicone adhesive.
9. A method for making a transdermal drug-containing dosage unit which comprises a laminate comprising:
contacting a backing layer substantially impervious to the drug to be delivered transdermally with a first polymeric adhesive matrix, having dispersed therein a drug and having a first initial rate of delivery of the drug;
contacting a second polymeric adhesive matrix, having dispersed therein the drug and having a second initial rate of delivery of the drug with the first adhesive matrix;
contacting a third polymeric adhesive matrix, having dispersed therein the drug and having a third initial rate of delivery of the drug with the second adhesive matrix; and
contacting a release liner with the third polymeric adhesive matrix;
wherein said initial rates of delivery of at least two of said matrices are different from one another.
10. The method of claim 9 , which further comprises contacting at least one additional drug-containing polymeric adhesive matrix with said first and second polymeric adhesive matrices.
11. The method of claim 9 , wherein each of said first, second and third initial rates of delivery is different from said other initial rates of delivery.
12. The method of claim 9 , wherein either said first and third adhesive matrices or said second adhesive matrix comprises an acrylic adhesive.
13. The method of claim 1 , wherein said drug comprises a cardiovascular drug, an androgenic steroid, an estrogen, a progestational agent, a drug which acts on the central nervous system, a nutritional agent, an anti-inflammatory agent, an antihistamine, a miotic, a dermatological agent, an anti-spasmodic, an anti-depressant, an anti-cancer drug, an anti-diabetic, an anti-estrogen, an anti-psychotic, an anti-infective agent, an anti-allergenic, an anti-pyretic, an anti-migraine agent or a tranquilizer.
14. The method of claim 1 , wherein said drug comprises an estrogen or a combination of an estrogen and a progestin.
15. The method of claim 14 , wherein said estrogen comprises estradiol or mono- or di-esters thereof which are transdermally absorbable.
16. The method of claim 14 wherein said progestin comprises norethindrone acetate or levonorgestrel.
17. The method of claim 1 wherein the transdermal drug-containing dosage unit comprises from about 0.1% to about 4.0% w/w of the drug.
18. The method of claim 14 wherein the transdermal drug-containing dosage unit comprises from about 0.1% to about 4.0% of said estrogen.
19. The method of claim 18 wherein the transdermal drug-containing dosage unit further comprises from about 0.1% to about 20% of the progestin.